Patient education should cover administration techniques for injectable formulations, proper storage requirements for peptide stability, and expected timelines for potential therapeutic effects based on preclinical data and limited clinical experience
Disclosures: Jane Giang: Nothing to Disclose, Sophia Hurr: Nothing to Disclose, Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant 1673 ASSESSING TRANSITIONS OF CARE AMONGST INPATIENTS WITH CIRRHOSIS DISCHARGED FROM A DIVERSE, URBAN LIVER TRANSPLANT CENTER: THE IMPORTANCE OF HEPATOLOGY INVOLVEMENT AND DISCHARGE DESTINATION Max Schechter 1 Katherine Ni 2 Zoe Verzani 3 Kimberline Chew 2 Jang Hyun Kim 2 Lewis Paulino 2 Danielle Garfunkel 2 Lital Aliasi-Sinai 4 Daniel Alvarez 2 Adejoke Johnson 2 Soaptarshi Paul 2 Hamza Sadhra 2 Clara Tow 2 Don Rockey 2 , 1 Albert Einstein College of Medicine, 2 Montefiore Medical Center, 3 Weill Cornell Medicine, 4 American Medical Prgm Tel Aviv Universit Background: Hospitalized patients with cirrhosis are at risk of readmission due to the severity and complexity of their disease
Dosing depends on the patient, their goals, the administration route, medical history, the product, and state laws
doi: 10.2174/138161210793176572, 3 AmandM.AdamsP.SchoberR.IserentantG.ServaisJ
Instead, EFSA used a combination of B12 biomarkers and European adult mean B12 intakes to estimate Adequate Intakes (AIs) for all life-stage and physiological groups
